INTRODUCTION AND OBJECTIVES: Prostate specific antigen (PSA), which is expressed by luminal epithelial cells in prostate was recently shown in the stromal compartment of BPH. Since the stromal compartment does not express PSA, epithelial barrier integrity in BPH nodules might be compromised through loss of cell junctions, resulting in the leakage of PSA and other secreted proteins into the stromal compartment and subsequently promoting BPH pathogenesis. E-cadherin, an important cell junction regulator, is found to be down-regulated in epithelial cells in clinical BPH specimens. Whether E-cadherin downregulation affects epithelial barrier permeability is unknown. This research is aimed at examining epithelial barrier permeability change in BPH and exploring the potential role of E-cadherin in prostatic luminal epithelial permeability.
METHODS: Explants derived from BPH patients were used to study epithelial barrier permeability in BPH nodules and its normal adjacent tissues by FITC-dextran assay. Normal prostate luminal epithelial cell line BHPrE1 was utilized to perform in vitro studies. Two independent siRNAs were used to knockdown E-cadherin expression. Permeability of BHPrE1 cell monolayers in trans-well inserts was evaluated by transepithelium electrical resistant (TER) assay and FITC-dextran trans-well assay. Cell viability was checked by cell counting assay and MTT assay. Expression of E-cadherin and tight junction proteins following siRNAs treatment were determined by reverse transcription-polymerase chain reaction (RT-PCR) and western-blot (WB).
RESULTS: FITC-dextran assay detected an increased epithelial barrier permeability in BPH tissues but not in the adjacent normal prostate in explants derived from BPH patients. Knockdown of E-cadherin in BHPrE1 cells decreased TER and increased FITC-dextran diffusion, indicating that E-cadherin knockdown disrupted epithelial barrier and increased monolayer permeability. E-cadherin knockdown had no impact on cell viability. E-cadherin knockdown also did not affect the expression of tight junction proteins ZO-1, ZO-2 and ZO-3.
CONCLUSIONS: Epithelial barrier permeability was increased in BPH and loss of E-cadherin is potentially an important underlying mechanism. Our results suggest blocking E-cadherin loss could be a potential approach to prevent or treat BPH.
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MP17-11 CONTRIBUTIONS OF PROSTATE VOLUME AND FIBROSIS TO BLADDER OUTLET OBSTRUCTION
Matthew D Grimes*, Will Lyon, Sijian Wang, Lori M Gettle, Wade A Bushman, Madison, WI INTRODUCTION AND OBJECTIVES: It has been proposed that prostatic fibrosis contributes to bladder outlet obstruction in men with BPH/LUTS. We used preoperative urodynamics and CT imaging to evaluate the contributions of prostatic enlargement and fibrosis to obstruction in a cohort of men who underwent surgery for BPH/LUTS. Prostate volume and radiodensity were determined from the preoperative CT scan. Hounsfield units (HU), a quantitative measure of radiodensity on CT scans used frequently as a surrogate marker for liver and lung fibrosis, was used as a surrogate marker for prostate fibrosis.
METHODS: We identified 34 men (mean age of 66 yrs, range 48-93 yrs) with complete pre-operative urodynamic evaluation for whom noncontrast axial pelvic CT scan images were available. Prostate volume was calculated using the formula for ellipsoid volume (L x W x H x 0.52). Mean prostate HU was determined by averaging the HU of ellipsoid selections of the proximal, middle, and distal prostate. The bladder outlet obstructive index (BOOI) was calculated from the formula P det Q max -2Q max and used to classify patients as obstructed (BOOI 40), equivocal (BOOI 20-40), or unobstructed (BOOI < 20). Ten men aged 20-40 years who underwent non-contrast axial CT scanning for flank pain were used as controls.
RESULTS: Mean BOOI was 56 (22 obstructed, 7 equivocal and 5 unobstructed). Mean prostate volume was significantly greater in patients with BPH/LUTS (mean 62 cc; range 19-217 cc) than in controls (mean 24 cc; range 14-33 cc) (<0.0001). Linear regression analysis revealed a significant positive relationship between volume and BOOI (p-value ¼ 0.04) in patients with BPH/LUTS. Mean prostate HU was significantly higher in men with BPH/LUTS (mean 37 HU, standard deviation 6 HU, range 28-49 HU) compared to controls (mean 41 HU, standard deviation 5 HU, range 35-51 HU) (p¼0.04) but linear regression analysis revealed no significant positive relationship between HU and BOOI (p ¼ 0.32).
CONCLUSIONS: Our studies affirm that prostate volume is significantly associated with urodynamic evidence of obstruction among men with BPH/LUTS. Prostatic radiodensity was significantly higher in men with BPH/LUTS compared to young healthy controls, but we found no significant association bettween prostate radiodensity and urodynamic evidence of obstruction in men with BPH/LUTS. Other studies have described profuse inflammatory infiltrate of benign prostatic hyperplasia (BPH) tissues, and that Th2 cytokines, particularly IL-4 and IL-13, are produced and secreted by infiltrating T-cells in these tissues. Because Th2 cytokines have been shown to mediate tissue fibrosis in the lung and liver, we hypothesized that Th2 cytokines secreted by inflammatory infiltrate may promote collagen accumulation and fibrosis in the prostate.
METHODS: N1 immortalized and primary prostate fibroblasts and lung fibroblasts (the later included as positive controls) were grown in serum free defined media supplemented with vehicle, TGFbeta, IL-4, and IL-13 alone or in combination with or without IL-4 or IL-13 inhibitors. Cells were evaluated by immunofluorescence for alphaSMA and collagen expression in situ, by immunoblot for IL-4Ralpha and IL13R1alpha expression, by WST assay for cell proliferation, by ELISA for protein expression, or by Sircol assay for collagen production.
RESULTS: Prostate and lung fibroblasts expressed the IL-4Ral-pha and IL-13R1alpha receptor proteins. N1 and primary prostate and lung fibroblasts underwent myofibroblast phenoconversion and significantly Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e215
